| 0.8317 -0.017 (-1.97%) | 06-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.28 | 1-year : | 1.5 |
| Resists | First : | 1.09 | Second : | 1.28 |
| Pivot price | 1.01  |
|||
| Supports | First : | 0.79 | Second : | 0.65 |
| MAs | MA(5) : | 0.87 |
MA(20) : | 1.02 |
| MA(100) : | 1.04 |
MA(250) : | 1.21 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.1 |
D(3) : | 17.3 |
| RSI | RSI(14): 38.3 |
|||
| 52-week | High : | 1.72 | Low : | 0.79 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LAB ] has closed above bottom band by 19.2%. Bollinger Bands are 147.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.86 - 0.86 | 0.86 - 0.87 |
| Low: | 0.82 - 0.82 | 0.82 - 0.83 |
| Close: | 0.82 - 0.83 | 0.83 - 0.84 |
Standard BioTools Inc., established in 1999 and based in South San Francisco, California, is a key player in providing advanced scientific tools. Formerly known as Fluidigm Corporation until its name change in April 2022, the company designs, produces, and distributes a variety of instruments, specialized consumables, and support services. These offerings cater to biomedical researchers and scientists worldwide, including those in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, assisting them in the creation of new therapeutics. The company operates through two main divisions: Proteomics and Genomics. Within these areas, it supplies instruments, disposable products, software, and services that enable the identification and functional analysis of proteins and genes. Standard BioTools’ innovative product line includes several advanced platforms: The SomaScan platform allows for the simultaneous measurement of numerous proteins, yielding extensive insights into biological pathways and disease progression. The CyTOF technology platform utilizes metal-tagged antibodies with time-of-flight mass spectrometry to overcome signal interference and boost multiplexing capabilities. Hyperion is a spatial biology platform that facilitates a deeper comprehension of tissue architecture by preserving spatial context while conducting high-dimensional molecular and proteomic analyses. The Biomark X9 system transforms high-throughput genomics, specifically designed for quantitative polymerase chain reaction (qPCR) applications. These instruments and consumables are intended strictly for research purposes. Standard BioTools serves a broad spectrum of clients, including academic research institutions, centers for translational research and medicine, cancer centers, clinical research laboratories, and companies in the biopharmaceutical, biotechnology, and plant/animal research industries. Furthermore, the company has established licensing agreements with prominent organizations such as the California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc.
Mon, 15 Jun 2026
Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders? - TradingView
Mon, 15 Jun 2026
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Fri, 12 Jun 2026
Viking backs Standard BioTools (LAB) merger with Treeline Biosciences - Stock Titan
Tue, 09 Jun 2026
Company that shut down Peninsula HQ now swept up in reverse merger - The Business Journals
Mon, 08 Jun 2026
Standard BioTools Inc. (LAB) Discusses Merger and Strategic Rationale - Slideshow (NASDAQ:LAB) 2026-06-08 - Seeking Alpha
Mon, 08 Jun 2026
Standard BioTools (NASDAQ: LAB) to merge with Treeline in $2.5B exchange‑ratio deal - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 391 (M) |
| Shares Float | 210 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 76.7 (%) |
| Shares Short | 13,130 (K) |
| Shares Short P.Month | 11,820 (K) |
| EPS | -0.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.44 |
| Profit Margin | 90.6 % |
| Operating Margin | -44.6 % |
| Return on Assets (ttm) | -8.1 % |
| Return on Equity (ttm) | -9.9 % |
| Qtrly Rev. Growth | 4.5 % |
| Gross Profit (p.s.) | 0.11 |
| Sales Per Share | 0.22 |
| EBITDA (p.s.) | -0.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -91 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -6.4 |
| PEG Ratio | 0 |
| Price to Book value | 0.57 |
| Price to Sales | 3.77 |
| Price to Cash Flow | -3.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|